about
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxibPharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugsLipoxygenase and cyclooxygenase metabolism: new insights in treatment and chemoprevention of pancreatic cancerAntimetastatic activity of a cyclooxygenase-2 inhibitorPhase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSerotonergic 5-HT(2B) receptor controls tissue-nonspecific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase CBiochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia.Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in miceMemy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice.Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.Lung cancer chemoprevention with celecoxib in former smokers.The expression of COX-2 in VEGF-treated endothelial cells is mediated through protein tyrosine kinaseLong term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenacCerebrovascular cyclooxygenase-1 expression, regulation, and role in hypothalamic-pituitary-adrenal axis activation by inflammatory stimuli.Antineovascular therapy, a novel antiangiogenic approach.Correlation between expression of cyclooxygenase-2 and angiogenesis in human gastric adenocarcinoma.Genetic ablation of cyclooxygenase-2 in keratinocytes produces a cell-autonomous defect in tumor formation.Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignanciesChemoprevention of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelinesThe molecular journey from ductal carcinoma in situ to invasive breast cancer.PPARdelta is pro-tumorigenic in a mouse model of COX-2-induced mammary cancer.Cyclooxygenase-2 in cancer and angiogenesis.Cyclooxygenase-1 or -2--which one mediates lipopolysaccharide-induced hypothermia?Pathophysiology of cyclooxygenase inhibition in animal models.Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives.COX-2 overexpression and -8473 T/C polymorphism in 3' UTR in non-small cell lung cancer.COXIBRAIN: results of the prospective, randomised, phase II/III study for the selective COX-2 inhibition in chronic subdural haematoma patients.Cyclooxygenase-2-regulated vascular endothelial growth factor release in gastric fibroblasts.Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth.Effects of parecoxib on the prevention of postoperative peritoneal adhesions in rats.Effects of NSAIDs on cryoprobe-induced gastric ulcer healing in rats.Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells.Anti-inflammatory effect of two isoforms of COX in H. pylori-induced gastritis in mice: possible involvement of PGE2.Interrelationship and expression profiling of cyclooxygenase and angiogenic factors in Indian patients with multiple myeloma.Biologic markers of angiogenesis: circulating endothelial cells in patients with advanced malignancies treated on phase I protocol with metronomic chemotherapy and celecoxib.Systematic review and meta-analysis of the benefit of celecoxib in treating advanced non-small-cell lung cancerCelecoxib in breast cancer prevention and therapy
P2860
Q24540362-741F28D3-7515-4B9C-957E-AA9F4AE1E8B3Q24792554-389BE421-338A-4D34-8D94-D1038B4A75C7Q24800010-8DC7DAF1-8117-4307-881C-0D0093195AB4Q28169082-19B110BC-BC0C-4932-A9C2-665E046398FDQ30439565-97E6FF90-86B3-47FC-AE80-531339E3B93AQ34074295-E6BCBBD0-4E57-415A-9A37-C1F4182DA7E1Q34082384-7EB57186-4DE8-44DD-BC65-FDAEFB661055Q34432972-A7751520-DB5B-4644-B35D-BB17051DE0D5Q34746895-714B4E3E-252B-4278-A829-D20EED750609Q34908885-A49BBB07-EC7C-45F5-B62E-E2283B6FA1E7Q35156358-F1985F76-848A-47F1-A965-94C93AD34794Q35609405-FCF3BE3B-529D-4BFE-AF66-D3CA5013B023Q35637500-1C3DB5B4-498A-473F-A0A8-A38A260D17D8Q35886515-66B8406B-EC61-4EA4-8DD9-973C5074AE13Q36066281-D33922C0-6C5E-4B81-B135-BD6903AB1EE7Q36178617-8F7B4061-8417-4A1D-85F2-E73B067F91E3Q36401953-D4A0E2A4-D3AF-449C-9D55-6FDDC3C4C801Q36420816-75677852-551A-402D-BD8C-5F30709B3E75Q37111529-CF11FC54-A6BF-4922-B033-BCBF3EDCAB19Q37126345-CC8F1958-FB93-4598-9813-76E5D9748C2FQ37144609-A0786D54-C340-4FEA-8D8E-F5A1F0A559ABQ37174279-046D848B-163F-49CD-9F9C-507F6136E688Q37298447-79A3A25D-B0B3-42A3-B27E-87B84349BC7EQ37398476-A64C72B0-D711-4099-89D9-F049F29264FAQ37528441-A8F64016-5C81-4497-B188-AD8AF2AA5FD2Q39146214-707BE07E-33D9-4D88-B450-6A68F6586CA5Q39412390-B83972CA-0DCB-49F4-96FD-48A6D28B558BQ40537203-8F91EACE-3DC2-49D6-8318-3358194BE0DCQ42010182-05634F31-8954-4E29-8BE1-6B35EAD03A8CQ42251910-47D62D98-44F7-49DD-A982-8A0A80ED32DCQ43817671-83486858-622B-443B-B4EA-7F6452BF358CQ44163463-91118F0B-042B-4006-948A-24D3281FE6B7Q44205593-EE83441E-1519-4117-87B4-29FA13B31187Q44534155-5FC20D79-D0A2-49EE-B27C-664E65D74C0CQ46568714-A493335E-82A9-4BF3-9AC9-FA28B10B2377Q46764721-144F0C73-7A21-412D-A260-F302B273CD78Q58797417-2C58316F-F379-4C3E-AF75-89B2966A1496Q59135502-271625F2-2D4C-468E-BE0C-62820D39789C
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
name
COX-2 inhibitors. A new class of antiangiogenic agents.
@ast
COX-2 inhibitors. A new class of antiangiogenic agents.
@en
type
label
COX-2 inhibitors. A new class of antiangiogenic agents.
@ast
COX-2 inhibitors. A new class of antiangiogenic agents.
@en
prefLabel
COX-2 inhibitors. A new class of antiangiogenic agents.
@ast
COX-2 inhibitors. A new class of antiangiogenic agents.
@en
P2093
P1476
COX-2 inhibitors. A new class of antiangiogenic agents.
@en
P2093
P356
10.1111/J.1749-6632.1999.TB08726.X
P407
P577
1999-01-01T00:00:00Z